Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.

Guide · Peptides · United States

KLOW, GLOW and Wolverine peptide blends: what is in them and are they legal?

KLOW, GLOW and Wolverine are marketing names for mixes of research peptides, not medicines. None is FDA approved, and none is covered by the October 2026 HHS compounding policy, which applies only to products with a single listed active ingredient.[5] Here is what each name usually contains, what the evidence shows, and the legal route that does exist.

What each blend usually contains

These names are not regulated, so what a product labeled KLOW or GLOW contains depends on who makes it. The descriptions below are attributed to the source that gives them.

KLOW, GLOW and Wolverine peptide blends: usual contents and US legal status
BlendWhat it usually containsUS status
WolverineBPC-157 and TB-500, marketed for muscle, tendon, ligament and wound healing[1][2]Not FDA approved. As a blend, outside the HHS policy, even though each of its two peptides is covered on its own[5]
KLOWTypically KPV, BPC-157, GHK-Cu and TB-500; formulations vary by source[3]Not FDA approved. As a blend, outside the HHS policy, and GHK-Cu is not one of the six policy peptides[5]
GLOWBuilt around GHK-Cu, sometimes paired with BPC-157, KPV or other peptides, marketed for skin repair and anti-aging[2]Not FDA approved. As a blend, outside the HHS policy, and GHK-Cu is not one of the six policy peptides[5]

For each ingredient on its own, see our pages on BPC-157, TB-500, KPV and GHK-Cu.

What the evidence shows

The research behind the Wolverine peptides is mostly preclinical, meaning animal and laboratory studies; no human clinical trial has confirmed that the stack works or established a safe dose.[1] Clinical reviewers describe the evidence for stacks as thinner than for single peptides, note that studies exist only for single agents, and say long-term data are lacking.[2]

Reported problems include injection-site reactions, and with unregulated products, contamination and infection risks.[2][1]

Under the interim HHS policy published on October 30, 2026, licensed 503A pharmacies may compound six peptides on a patient-specific prescription: BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon. Each compounded product may contain only one listed active ingredient, so a blend is outside the policy. HHS says the policy does not grant FDA approval or establish safety and effectiveness.[4][5]

If a clinician thinks one of these peptides is appropriate for you, our guide to getting BPC-157 and the other five peptides on prescription explains how it works and what US programs charge.

Frequently asked questions

What is in the KLOW peptide blend?

KLOW typically refers to a combination of KPV, BPC-157, GHK-Cu and TB-500, though formulations vary depending on the source. It is not an FDA-approved product.

What is in the GLOW peptide blend?

GLOW blends include GHK-Cu and are sometimes paired with BPC-157, KPV or other peptides. They are marketed for skin repair and anti-aging and are not FDA approved.

What is the Wolverine peptide stack?

Wolverine combines two synthetic peptides, BPC-157 and TB-500, marketed for muscle repair and healing. The research behind them is mostly preclinical, and the stack is not FDA approved.

Are peptide blends legal in the US?

No blend is FDA approved. The interim HHS compounding policy of October 2026 covers a compounded product only when it contains a single listed active ingredient, so a pharmacy compounding under that policy cannot make a blend. Single-ingredient BPC-157, TB-500 or KPV may be compounded on a prescription under the policy; GHK-Cu is not one of the six peptides it covers.

Are peptide blends safe?

There is not enough evidence to say. Clinical reviewers note that evidence for stacks is thinner than for single peptides, that studies exist only for single agents, and that long-term data are lacking. Reported problems include injection-site reactions and contamination or infection risks with unregulated products.

Sources

  1. Healthline, "Wolverine peptides", written by Shanika Wigley, medically reviewed by Ami Patel, PharmD, updated October 14, 2026. www.healthline.com. Read November 15, 2026.
  2. MDLinx, "Your clinical guide: Managing patients using 'peptide stacks' for chronic pain and anti-aging", Alpana Mohta, MD, May 4, 2026 (modified October 21, 2026). www.mdlinx.com. Read November 15, 2026.
  3. Dr. Kristi Sawicki, PhD, "The KLOW Peptide Stack", August 11, 2026. drkristisawicki.substack.com. Read November 15, 2026.
  4. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket HHS-OASH-2026-0496), Federal Register public inspection copy. public-inspection.federalregister.gov. Read November 15, 2026.
  5. 503A peptide enforcement discretion policy, Appendix B: conditions and covered routes of administration. www.hhs.gov. Read November 15, 2026.

This page is information, not medical or legal advice. It recommends no peptide or blend and gives no dosing guidance. Talk to a licensed clinician about what is appropriate for you.